tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
DE | FR | EN | PRINT
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecoimage tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecomedical laborreagenzien medizin produkte teco
tecoimage tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecomedical laborreagenzien medizin produkte teco

Komplementäre Proteine

Produktname C9 Protein

Purified human complement component C9

Kat-Nr. A407
Anwendung

Complement component C9 is unique to the terminal complement pathway. It is a single chain protein with a molecular weight of 69 kD and is present in plasma at approximately 60 mg/L. Together with the other proteins of the terminal pathway, C9 forms the membrane attack complex or MAC.

Specifications:
Concentration: 1.0 mg/ml
Volume/Vial: 250 µl/vial
Storage: at or below -70°C
Purity: > 95%
Buffer: PBS

Functional Testing:
All Quidel complement components are tested for functional activity in a standard lytic or applicable functional assay and for biochemical purity by SDS- polyacrylamide gel electrophoresis. Please refer to the Certificate of Analysis for lot specific information on functional titer.

Applications:
Quidel's purified human complement components are useful in a wide variety of immunochemical and research applications.

References:

  • Nicholson-Weller, Butko, P, Wessels, M., Role of Complement Component C1q in IgG independent Opsonophagocytosis of Group B Streptococus, J. Immunol 163:2761-2768, 1999.
  • C. Koski, Dashell, S., Sublytic terminal complement complex decreases Po gene expression in schwan cells, J Neurochem 73(6):2321-2330 (1999).
  • C. Liu, et al., Interaction between the terminal complement pathway complex C5b-7 and anionic phospholipids, Blood 93(7)2291-2301(1999).

Knochenparameter, Angiogenese, Tierassays, Spezielle Parameter, Knochenstoffwechsel, Kalziumstoffwechsel, KnorpelstoffwechselZurück zur Übersicht      Druckansicht
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco
 
tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco tecomedical laborreagenzien medizin produkte teco